Therapy News and Research

RSS

New standard treatment for early stage breast cancer

Spanish Oncology has established a new standard treatment for Breast Cancer at early stages thanks to the results of the study 9805/Target 0 funded by Spanish Breast Cancer Research Group and sponsored by Sanofi Aventis.

4 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

New clues into mechanisms underlying antiphospholipid syndrome

Thanks to findings by UT Southwestern Medical Center researchers, individuals with a potentially life-threatening condition predisposing them to blood clots, or thrombosis, might someday receive therapy to prevent the condition.

4 Dec 2010

Research findings could provide breakthrough for development of effective therapies for NSCLC

Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.

4 Dec 2010

New article questions role of amenities in hospital care

From hotel-style room service to massage therapy to magnificent views, hospitals are increasingly touting their luxury services in a bid to gain market share, especially those in competitive urban markets. An important new article, published today in the New England Journal of Medicine, raises crucial questions about the role of amenities in hospital care, explaining that how we decide to value the patient experience can have a significant effect on health care costs.

3 Dec 2010

Prostate cancer imaging shows real-time tumor metabolism

A UCSF research collaboration with GE Healthcare has produced the first results in humans of a new technology that promises to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor's metabolism.

3 Dec 2010

New book on managing worry, anxiety and fear

Americans' danger detectors are cranked up way too high these days, but we don't have to be held hostage by our anxiety, according to a new book on coping with stress by a Northwestern Medicine psychologist.

3 Dec 2010

Healthy lifestyle choices, emergency room interventions can help prevent first-time strokes

Healthy lifestyle choices and emergency room interventions can help prevent first-time strokes, according to revised American Heart Association/American Stroke Association guidelines.

3 Dec 2010

CRT therapy is cost-effective for symptomatic heart failure patients: REVERSE trial

Medtronic, Inc. announced findings from an economic sub-study of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial published in the European Heart Journal demonstrating for the first time that cardiac resynchronization therapy (CRT) is cost-effective in mildly symptomatic heart failure (HF) patients.

3 Dec 2010

Scripps scientists find way to transform mature human cells into stem cells

Scripps Research Institute scientists have made a significant leap forward in the drive to find a way to safely reprogram mature human cells and turn them into stem cells, which can then change into other cell types, such as nerve, heart, and liver cells. The ability to transform fully mature adult cells such as skin cells into stem cells has potentially profound implications for treating many diseases.

3 Dec 2010

Doctors still prescribe higher-dose menopausal hormone therapy pills

Doctors across the country are still prescribing higher-dose menopausal hormone therapy pills, despite clinical evidence that low doses and skin patches work just as well and carry fewer health risks. That's what researchers at the Stanford University School of Medicine found in a study that will be published online Dec. 2 in Menopause: The Journal of the North American Menopause Society.

3 Dec 2010

CDC: Hip replacement surgical procedures are more prevalent in the U.S.

According to the Centers for Disease Control and Prevention (CDC), hip replacements are among the most common surgical procedures in the United States; and with osteoarthritis and obesity on the rise, demand for the procedure is expected to grow.

3 Dec 2010

MU nanomedicine experts form new partnership with Shasun Pharmaceuticals

University of Missouri leaders celebrated a nanomedicine milestone today as they announced the creation of a new drug development company. The new company forms a partnership between university researchers and an international pharmaceutical firm to advance testing of a potential cancer treatment created at MU.

3 Dec 2010

Olympus PlasmaButton- vaporization technology now usable with Gyrus ACMI SuperPulse- Generator platform

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products among other core businesses, announced today that its revolutionary PlasmaButton- vaporization technology can now be used with the Gyrus ACMI SuperPulse- Generator platform. Together, the PlasmaButton electrode and SuperPulse Generator provide physicians and patients with a new, virtually bloodless treatment option for benign prostate hyperplasia (BPH) or enlarged prostate.

From Evident Corporation - Life Sciences 3 Dec 2010

New study offers hope for children with MPS I genetic disorder

A new study offers hope for children born with a rare genetic disease, according to a paper published by the American Association for the Advancement of Science.

3 Dec 2010

TUM physicist's new approach expected to improve image contrast with low radiation

The DFG cited Pfeiffer's research in biomedical imaging, and in particular his pioneering work in X-ray phase-contrast imaging. His systematic approach has laid the foundation for applications of this technique in medicine and industry, where it is expected to deliver improved image contrast with lower doses of radiation.

3 Dec 2010

White House marks World AIDS Day

Commemorating World AIDS Day on Wednesday President Barack Obama called for continuing to fight HIV/AIDS domestically and abroad, Agence France-Presse reports (12/1).

2 Dec 2010

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced results from its first Phase 3 trial post hoc analysis in which the higher body mass index (BMI) of the U.S. population relative to the Indian population was a likely key contributor to the more positive effects of D-tagatose in the lowering of HbA1c levels in the U.S. population. Initial results were announced on October 7.

2 Dec 2010

FDA approves IDE application to initiate Tryton Side Branch Stent System for coronary artery disease

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced U.S. Food and Drug Administration (FDA) conditional approval for an Investigational Device Exemption (IDE) application to initiate the pivotal trial to evaluate the Tryton Side Branch Stent System for the treatment of coronary artery disease.

2 Dec 2010

ROCHE, Baylor Research Institute partner in human immunology research

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced today that it has formed a three-year partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI.

2 Dec 2010